Stay updated on Gevokizumab with Anti-cancer Therapies in Metastatic Cancers Clinical Trial
Sign up to get notified when there's something new on the Gevokizumab with Anti-cancer Therapies in Metastatic Cancers Clinical Trial page.

Latest updates to the Gevokizumab with Anti-cancer Therapies in Metastatic Cancers Clinical Trial page
- Check6 days agoChange DetectedNew locations were added to the study record, expanding the geographic footprint of the trial. The additions cover sites in the United States (California, Missouri, Tennessee, Michigan), Australia (Victoria), Canada (Alberta, Ontario), Germany (Hesse, Saxony), Japan (Aichi-ken, Chiba, Osaka, Shizuoka, Tokyo), Spain (Andalusia, Barcelona).SummaryDifference1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedA minor version revision was applied (v3.3.2; v3.3.1 removed). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check35 days agoChange DetectedThe site revision was updated from v3.2.0 to v3.3.1. There is no indication of changes to study content or functionality.SummaryDifference0.0%

- Check42 days agoChange Detected- Added a new study site: Tainan, Taiwan, 70403. - Removed the entry: Tainan City, Taiwan, 70403.SummaryDifference0.3%

- Check56 days agoChange DetectedNo significant content changes were detected on the Study Details page; only minor formatting and layout adjustments observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check85 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference3%

Stay in the know with updates to Gevokizumab with Anti-cancer Therapies in Metastatic Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gevokizumab with Anti-cancer Therapies in Metastatic Cancers Clinical Trial page.